Anticoagulants: Difference between revisions

No edit summary
Line 1: Line 1:
[[File:Anticoagulants.png|thumb]]
[[File:Anticoagulants.png|thumb]]
==Contraindications to Anticoagulation<ref>Bates SM, Ginsberg JS. Treatment of deep-vein thrombosis. N Engl J Med. 2004;351(3):268–277.</ref>
*Absolute:
**Active bleeding
**Severe bleeding diathesis or platelet count <20K
**Neurosurgery, ocular surgery, or intracranial bleeding in the last 10 days
*Relative:
**Mild-to-moderate bleeding diathesis or thrombocytopenia
**Brain metastases
**Recent major trauma
**Major abdominal surgery within the past 2 days
**GI or GU bleeding within the past 14 days
**Endocarditis
**Severe hypertension (>200/120mmHg) at presentation


==Vitamin K Antagonist==
==Vitamin K Antagonist==

Revision as of 23:16, 18 January 2021

Anticoagulants.png

==Contraindications to Anticoagulation[1]

  • Absolute:
    • Active bleeding
    • Severe bleeding diathesis or platelet count <20K
    • Neurosurgery, ocular surgery, or intracranial bleeding in the last 10 days
  • Relative:
    • Mild-to-moderate bleeding diathesis or thrombocytopenia
    • Brain metastases
    • Recent major trauma
    • Major abdominal surgery within the past 2 days
    • GI or GU bleeding within the past 14 days
    • Endocarditis
    • Severe hypertension (>200/120mmHg) at presentation

Vitamin K Antagonist

Blocks activation of vitamin K dependent prothrombotic factors II, VII, IX, X and blocks synthesis of vitamin K dependent ANTI-thrombotic proteins C and S

Heparins

Bind to and activate antithrombin, which in turns inactivates factor Xa and thrombin

Factor Xa Inhibitors

Inhibits Factor Xa, leading to inactivation of thrombin

Direct Thrombin Inhibitors

Self-explanatory

See Also

  1. Bates SM, Ginsberg JS. Treatment of deep-vein thrombosis. N Engl J Med. 2004;351(3):268–277.